GMMMG logo

NHS photos

NHS logo

News

<< Back

News Summary

From this page you will be able to access a summary of additions or changes to the GMMMG website during March 2017

March 2017

 

Formulary and Managed Entry Subgroup (FMES)

23.3.17

A supporting document on use of PCSK-9 Inhibitors according to the NICE TAs has been approved and is now available here

This will be linked within the GMMMG Formulary shortly.

High Cost Drugs Subgroup (HCDSG)

16.3.17

Blueteq forms for the use of Adalimumab, Golimumab, Infliximab and Vedolizumab for UC and CD have been developed for GM use and are now open for a 2 week consultation period, to view the forms and comment please follow this link.

Pathways and Guidelines Development Subgroup (PaGDSG)

28.3.17

The following Shared Care Protocols have had minor amendments made to them in March 2017:

  • Ciclosporin in Dermatology– addition of a sentence in section 1 to say that “At time of writing Capimune is most cost effective option for patients to be commenced on treatment within secondary care”

14.3.17

The following Shared Care Protocols had minor amendments to them approved at the March 2017 meeting of the Pathways and Guidelines Development Subgroup:

  • The Prescribing and Monitoring of Oral Second Generation (Atypical) Antipsychotics for Adults – changes to monitoring for prolactin. Prolactin is now monitored at 12 months and then annually thereafter.

13.3.17

The Pathways and Guidelines Development Subgroup has approved an academic detailing aid to  supported the implementation of the a GM COPD management plan. It can be found on the  GMMMG website (pathways section)

13.3.17

Agenda for March 2017 meeting, plus the minutes of January 2017 meeting  of Pathways and Guidelines Development Subgroup have now been published and are available on site.

6.3.17

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester Trans-Anal Irrigation (TAI) Pathway is in development. We now seek the comments of all GM NHS healthcare professionals on this. This consultation period is open until 5:00pm on Friday 31st March 2017. Comments should be submitted here after which it will be reviewed, amended as required and then taken to GMMMG for final approval. The Pharmaceutical Industry is invited to comment on factual inaccuracies only.

<< Back

Line

TERMS AND CONDITIONS    |    CONTACT US    |    ABOUT US    |    ARCHIVE

RSS Feed
 
spacer